Comparison
2p25 3 Microduplication Syndrome C6012304 vs 14q11 2 Microduplication Syndrome C4749855
Clinical comparison between 2p25 3 Microduplication Syndrome and 14q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
2p25 3 Microduplication Syndrome C6012304
A rare chromosomal condition involving extra genetic material on chromosome 2. Features vary widely based on the genes involved. Treatment focuses on managing specific symptoms.
14q11 2 Microduplication Syndrome C4749855
A rare genetic condition involving a small extra piece of chromosome 14. Features vary and may include developmental delays. Management focuses on supportive therapies and monitoring.
6 comparison axes
Onset
2p25 3 Microduplication Syndrome C6012304
0-5
14q11 2 Microduplication Syndrome C4749855
0-5
Onset patterns differ
Severity
2p25 3 Microduplication Syndrome C6012304
severe
14q11 2 Microduplication Syndrome C4749855
moderate
Different severity levels
Chronic
2p25 3 Microduplication Syndrome C6012304
Chronic
14q11 2 Microduplication Syndrome C4749855
Chronic
Differing course
Communicable
2p25 3 Microduplication Syndrome C6012304
No
14q11 2 Microduplication Syndrome C4749855
No
Different transmission
Body System
2p25 3 Microduplication Syndrome C6012304
congenital
14q11 2 Microduplication Syndrome C4749855
congenital
Same/different system
Category
2p25 3 Microduplication Syndrome C6012304
rare-disease
14q11 2 Microduplication Syndrome C4749855
genetic
Different category
Bottom line
2p25-3-microduplication-syndrome-C6012304 and 14q11-2-microduplication-syndrome-C4749855 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 2p25 3 Microduplication Syndrome C6012304 | 14q11 2 Microduplication Syndrome C4749855 | Discriminating power |
|---|---|---|---|
| Developmental presentation | Features vary widely and depend on the duplicated genes; no single pattern is established. | Features vary and may include developmental delay, although this is not definitive for every person. | Moderate |
| Overall clinical severity | Classified in the source as severe, without specified organ findings. | Classified in the source as moderate, with supportive care emphasized. | Moderate |
| Age at recognition | Onset is listed as 0–5 years, but exact timing is not established. | Onset is also listed as 0–5 years, so age alone does not distinguish them. | Low |
When to favor each condition
Choose 2p25 3 Microduplication Syndrome C6012304 when
Chromosomal testing identifies extra material at 2p25.3
The chromosomal location, not symptoms alone, establishes this condition.
High
A broad, gene-dependent congenital phenotype is reported
The source states that features vary widely according to involved genes.
Moderate
Care planning anticipates potentially severe needs
The supplied severity is severe, but individual prognosis remains uncertain.
Low
Choose 14q11 2 Microduplication Syndrome C4749855 when
Testing identifies a small duplication at 14q11.2
The specific chromosomal segment distinguishes this condition.
High
Developmental delay is present with otherwise variable findings
Delay is mentioned as a possible feature, not a required diagnosis.
Moderate
Management centers on monitoring and supportive therapy
This matches the supplied management description.
Moderate
How key tests differ
| Test | 2p25 3 Microduplication Syndrome C6012304 | 14q11 2 Microduplication Syndrome C4749855 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | Extra material involving 2p25.3 may be detected. | A small extra segment at 14q11.2 may be detected. | The genomic location distinguishes the findings; clinical correlation is required. |
| Gene-content review | Interpretation depends on which genes are duplicated. | Interpretation likewise depends on the duplicated segment and genes. | No universal gene list or cutoff is supplied. |
| Developmental assessment | Results may vary; no characteristic profile is established. | Assessment may identify developmental delay in some people. | An abnormal assessment supports care planning but does not by itself diagnose either syndrome. |
Prognosis comparison
2p25 3 Microduplication Syndrome C6012304
- Outcome
- A chronic and potentially severe course is suggested, but individual outcome is not established.
- Factors
- Duplicated genes, identified symptoms, and response to supportive care may influence course.
14q11 2 Microduplication Syndrome C4749855
- Outcome
- A chronic, generally moderate course is suggested, with variable developmental impact.
- Factors
- Extent of duplication, developmental findings, and access to supportive therapies may matter.
Time frame: Both are listed with onset from birth to age 5 and a chronic course; longer-term outcomes are not specified.
Genomic findings and clinical assessment should guide prognosis; population estimates are not supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Variable congenital complications | Possible complications are not specifically established. Specific complications are also not established. Do not infer organ involvement without individual evaluation. |
| Developmental needs | Needs may be substantial because severity is listed as severe. Needs may include developmental support, with moderate listed severity. Severity labels do not predict every person's course. |
| Long-term health burden | A chronic course is indicated, but outcomes are unspecified. A chronic course is also indicated, with monitoring emphasized. Neither description establishes mortality or a fixed complication rate. |
Patient education highlights
- HighDiagnosis depends on testing
Symptoms overlap and vary; chromosomal testing and clinician review are needed to distinguish these conditions.
- HighCare is individualized
Treatment or management focuses on the person's identified needs rather than a single standard regimen.
- MediumUncertainty is expected
Available descriptions do not establish exact symptoms, laboratory cutoffs, prevalence, or prognosis.